<DOC>
	<DOCNO>NCT01059448</DOCNO>
	<brief_summary>This extension study subject participate Protocol 20090061 ( NCT00950989 ) . All subject study receive 210mg injection AMG827 treatment Rheumatoid Arthritis 5 year .</brief_summary>
	<brief_title>Safety Efficacy AMG 827 Subjects With RA</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Subject provide informed consent . Subject randomize study 20090061 complete week 16 evaluation . Negative test hepatitis B virus ( HBV ) surface antigen , hepatitis C virus ( HCV ) antibody , and/or human immunodeficiency virus ( HIV ) subject clinically indicate ( eg , know recent exposure ) opinion investigator . Subject must test negative Tuberculosis . Subject SAE report 20090061 consider related IP . Subject currently experience infection CTCAE grade 2 ( require oral antibiotic ) high . Subject ineligible infection resolve opinion investigator . For subject &gt; 4 week week 16 visit 20090061 plan first IP dose 20090402 , subject laboratory abnormality screen , include : Elevated aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ; &gt; 1.5x upper limit normal ) Serum total bilirubin ≥1.5 mg/dL Hemoglobin &lt; 11 g/dL Platelet count &lt; 125,000 /mm3 White blood cell count &lt; 3,000 cells/mm3 Absolute neutrophil count &lt; 2000/mm3 Estimated creatinine clearance &lt; 50 mL/min ( CockroftGault formula , central lab calculate value provide site ) Subject significant concurrent medical condition , include : Type 1 diabetes Poorly control type 2 diabetes ( Hemoglobin A1c &gt; 8.5 ) Symptomatic heart failure ( New York Heart Association class II , III , IV ) Myocardial infarction within last year Current history unstable angina pectoris within last year Uncontrolled hypertension define rest blood pressure &gt; 150/90 mmHg prior first IP dose ( confirmed repeat assessment ) Severe chronic pulmonary disease ( eg , require oxygen therapy ) Major chronic inflammatory disease connective tissue disease rheumatoid arthritis ( eg , systemic lupus erythematosus ) , exception secondary Sjögren 's syndrome Multiple sclerosis demyelinate disease Active malignancy , include evidence cutaneous basal squamous cell carcinoma melanoma , history cancer ( except successfully treat situ cervical cancer squamous basal cell carcinoma skin ) Any condition , opinion investigator , might cause study detrimental subject Subject pregnant breast feeding , plan become pregnant enrolled study , subject 's last study visit include followup period . Female subject willing abstain sexual intercourse use 2 highly effective form birth control duration study least 40 day last dose ( except woman least 3 year postmenopausal surgically sterile ) . Highly effective method birth control woman include limited birth control pill , Depo Provera® injection , contraceptive implant , occlusive cap ( barrier method ) combination barrier method use man . Male subject willing abstain sexual intercourse use 2 highly effective form birth control duration study , plus additional 16 week last dose ( except men surgically sterile whose female partner least 3 year postmenopausal surgically sterile ) . Highly effective method birth control include limited condom combination hormonal birth control barrier method use woman . Male subject ( include vasectomise male ) pregnant female partner willing use effective method ensure unborn child expose AMG 827 via semen . Effective method ensure unborn child expose AMG 827 via semen include condom abstinence . Subject use follow within 14 day prior IP initiation Nonbiologic diseasemodifying antirheumatic drug ( DMARD ) allow 20090061 Intraarticular , intramuscular , intravenous corticosteroid , include adrenocorticotropic hormone Subject use follow within 3 month prior IP initiation Leflunomide Live vaccine Commercially available experimental biologic DMARD except AMG 827 Subject receive gold therapy within 6 month prior IP initiation . Subject receive another investigational agent ( AMG 827 ) participate investigational device study subsequent 20090061 . Other investigational procedure exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Amgen</keyword>
	<keyword>RA</keyword>
	<keyword>AMG 827</keyword>
	<keyword>20090061</keyword>
</DOC>